BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 7787250)

  • 1. p53 mutations in bladder carcinoma cell lines.
    Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
    Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.
    Matozaki T; Sakamoto C; Suzuki T; Matsuda K; Uchida T; Nakano O; Wada K; Nishisaki H; Konda Y; Nagao M
    Cancer Res; 1992 Aug; 52(16):4335-41. PubMed ID: 1322785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL; Ling YF; Lai MD
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Liu Y; Bodmer WF
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
    Reiss M; Brash DE; Muñoz-Antonia T; Simon JA; Ziegler A; Vellucci VF; Zhou ZL
    Oncol Res; 1992; 4(8-9):349-57. PubMed ID: 1486218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
    Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
    Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer.
    Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
    Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):611-6. PubMed ID: 9264274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
    Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
    Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
    Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
    Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
    Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
    Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
    Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
    Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression.
    Ruggeri B; Caamano J; Goodrow T; DiRado M; Bianchi A; Trono D; Conti CJ; Klein-Szanto AJ
    Cancer Res; 1991 Dec; 51(24):6615-21. PubMed ID: 1742735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.